Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise

Arwa  Abdel-Aal; Karin  Lisspers; Siân Williams; Peymane Adab; Rachel Adams; Dhiraj  Agarwal; Amanda  Barnard; Izolde  Bouloukak; Job FM  van Boven; Niels  Chavannes; Andy Dickens; Frederik  van Gemert; Mercedes  Escarrer; Shamil Haroon; Alex  Kayongo; Bruce  Kirenga; Janwillem W H  Kocks; Daniel  Kotz; Chris  Newby; Cliodna a M McNulty; Esther  Metting; Luis  Moral; Sophia  Papadakis; Hilary Pinnock; David Price; Dermot  Ryan; Sally J Singh; Jaime Correia-de-Sousa; Björn  Ställberg; Stanley J  Szefler; Steph J.C.  Taylor; Ioanna Tsiligianni; Alice Turner; David Weller; Osman  Yusuf; Aizhamal K  Tabyshova; Rachel Jordan

doi:10.1038/s41533-021-00266-4

Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise

Arwa Abdel-Aal, Karin Lisspers, Siân Williams, Peymane Adab, Rachel Adams, Dhiraj Agarwal, Amanda Barnard, Izolde Bouloukak, Job FM van Boven, Niels Chavannes, Andy Dickens, Frederik van Gemert, Mercedes Escarrer, Shamil Haroon, Alex Kayongo, Bruce Kirenga, Janwillem W H Kocks, Daniel Kotz, Chris Newby, Cliodna a M McNultyEsther Metting, Luis Moral, Sophia Papadakis, Hilary Pinnock, David Price, Dermot Ryan, Sally J Singh, Jaime Correia-de-Sousa, Björn Ställberg, Stanley J Szefler, Steph J.C. Taylor, Ioanna Tsiligianni, Alice Turner, David Weller, Osman Yusuf, Aizhamal K Tabyshova, Rachel Jordan

Applied Health Research

Research output: Contribution to journal › Article › peer-review

52 Downloads (Pure)

Abstract

Respiratory diseases remain a significant cause of global morbidity and mortality and primary care plays a central role in their prevention, diagnosis and management. An e-Delphi process was employed to identify and prioritise the current respiratory research needs of primary care health professionals worldwide. One hundred and twelve community-based physicians, nurses and other healthcare professionals from 27 high-, middle- and low-income countries suggested 608 initial research questions, reduced after evidence review by 27 academic experts to 176 questions covering diagnosis, management, monitoring, self-management and prognosis of asthma, COPD and other respiratory conditions (including infections, lung cancer, tobacco control, sleep apnoea). Forty-nine questions reached 80% consensus for importance. Cross-cutting themes identified were: a need for more effective training of primary care clinicians; evidence and guidelines specifically relevant to primary care, adaption for local and low-resource settings; empowerment of patients to improve self-management; and the role of the multidisciplinary healthcare team.

Original language	English
Article number	6
Number of pages	12
Journal	NPJ Primary Care Respiratory Medicine
Volume	32
Issue number	1
Early online date	28 Jan 2022
DOIs	https://doi.org/10.1038/s41533-021-00266-4
Publication status	Published - Dec 2022

Bibliographical note

Funding Information:
P.A. holds grants related to respiratory epidemiology from the NIHR. She chairs the NIHR Public Health Research Funding Committee. Jv.B. has received consultancy fees, honorarium and research funding from AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini, Novartis, Nutricia, Pill Connect, Teva and Trudell Medical to consult, give lectures, provide advice and conduct independent research, all paid to his institution. J.C.S. has in the last 3 years received payment for participating in educational activities from Boheringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis and Mundipharma. R.J. reports grants from the NIHR and participation in a Boehringer Ingelheim primary care advisory board during this project. J.K. reports grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim, grants and personal fees from Chiesi Pharmaceuticals, grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, grants from MundiPharma, grants from TEVA, outside the submitted work, all paid to his institution; and J.K. holds 72.5% of shares in the General Practitioners Research Institute. K.L. has received personal fees for lectures and educational activities from AstraZeneca, Novartis, Boehringer Ingelheim and Chiesi and served on advisory boards arranged by AstraZeneca, GlaxoSmithKline, Novartis and Boehringer Ingelheim. L.M. has received payment for participating in educational activities, consultancy, or support to attend clinical meetings from Hero España, Merck-Allergopharma, ALK-Abelló, Laboratorios Jofre-Roig, Laboratorios Leti, Faes Farma, Novartis, Inmunotek, GSK, and Alter. D.P. has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundi-pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. H.P. in the last 3 years was paid by Teva to write a piece on supported self-management for their website. Organisations with which she is involved, or conferences/meetings at which she has spoken receive multi-company sponsorship. D.R. has in the last 3 years received payment for participating in educational activities, consultancy or support to attend clinical meetings from: AZ,BI, GSK, Chiesi, Novartis, Trudell, Meda, Regeneron and Medscape. He is a board member of the Primary care and allied health section of the European Academy of Allergy and clinical Immunology and vice president of the Respiratory Effectiveness Group. B.S. has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, MEDA and TEVA and has served on advisory boards arranged by AstraZeneca, Novartis, GlaxoSmithKline, Boehringer Ingelheim and MEDA. S.S. has served as a consultant for Boehringer Ingelheim, Genentech, GlaxoSmithKline, AstraZeneca, Propeller Health, Sanofi, and Regeneron; and received a grant from Propeller Health. All payments were made to his university. A.T. has grants for respiratory research from AstraZeneca, Chiesi and CSL Behring, and has additional consultancy or honoraria for educational work for GSK and Boehringer Ingelheim. S.T. holds grants related to COPD and asthma from the NIHR. I.T. has in the last 3 years received payment for participating in educational activities, consultancy or received grants from: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and ELPEN. She is the Editor in Chief of the npjPCRM. O.Y. holds a grant related to respiratory health from the NIHR. A.B., R.A., A.A.A., D.A., I.B., N.C., A.D., M.E., Fv.G., S.H., A.K., B.K., D.K., E.M., C.Mc., C.N., S.P., S.J.S., D.W., S.W. and A.K.T. declare no competing interests.

Publisher Copyright:
© 2022, The Author(s).

Keywords

e-Delphi
primary care
research priorities
respiratory disease
asthma
COPD
tobacco

ASJC Scopus subject areas

Public Health, Environmental and Occupational Health
Family Practice
Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41533-021-00266-4Licence: Creative Commons: Attribution (CC BY)

AbdelAalA2022PrioritisingFinal published version, 1.54 MBLicence: Creative Commons: Attribution (CC BY)

Cite this

Abdel-Aal, A., Lisspers, K., Williams, S., Adab, P., Adams, R., Agarwal, D., Barnard, A., Bouloukak, I., van Boven, J. FM., Chavannes, N., Dickens, A., van Gemert, F., Escarrer, M., Haroon, S., Kayongo, A., Kirenga, B., Kocks, J. W. H., Kotz, D., Newby, C., ... Jordan, R. (2022). Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise. NPJ Primary Care Respiratory Medicine, 32(1), Article 6. https://doi.org/10.1038/s41533-021-00266-4

@article{98d83949e4b44308ac31e310a4a23d0b,

title = "Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise",

abstract = "Respiratory diseases remain a significant cause of global morbidity and mortality and primary care plays a central role in their prevention, diagnosis and management. An e-Delphi process was employed to identify and prioritise the current respiratory research needs of primary care health professionals worldwide. One hundred and twelve community-based physicians, nurses and other healthcare professionals from 27 high-, middle- and low-income countries suggested 608 initial research questions, reduced after evidence review by 27 academic experts to 176 questions covering diagnosis, management, monitoring, self-management and prognosis of asthma, COPD and other respiratory conditions (including infections, lung cancer, tobacco control, sleep apnoea). Forty-nine questions reached 80% consensus for importance. Cross-cutting themes identified were: a need for more effective training of primary care clinicians; evidence and guidelines specifically relevant to primary care, adaption for local and low-resource settings; empowerment of patients to improve self-management; and the role of the multidisciplinary healthcare team.",

keywords = "e-Delphi, primary care, research priorities, respiratory disease, asthma, COPD, tobacco",

author = "Arwa Abdel-Aal and Karin Lisspers and Si{\^a}n Williams and Peymane Adab and Rachel Adams and Dhiraj Agarwal and Amanda Barnard and Izolde Bouloukak and {van Boven}, {Job FM} and Niels Chavannes and Andy Dickens and {van Gemert}, Frederik and Mercedes Escarrer and Shamil Haroon and Alex Kayongo and Bruce Kirenga and Kocks, {Janwillem W H} and Daniel Kotz and Chris Newby and McNulty, {Cliodna a M} and Esther Metting and Luis Moral and Sophia Papadakis and Hilary Pinnock and David Price and Dermot Ryan and Singh, {Sally J} and Jaime Correia-de-Sousa and Bj{\"o}rn St{\"a}llberg and Szefler, {Stanley J} and Taylor, {Steph J.C.} and Ioanna Tsiligianni and Alice Turner and David Weller and Osman Yusuf and Tabyshova, {Aizhamal K} and Rachel Jordan",

note = "Funding Information: P.A. holds grants related to respiratory epidemiology from the NIHR. She chairs the NIHR Public Health Research Funding Committee. Jv.B. has received consultancy fees, honorarium and research funding from AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini, Novartis, Nutricia, Pill Connect, Teva and Trudell Medical to consult, give lectures, provide advice and conduct independent research, all paid to his institution. J.C.S. has in the last 3 years received payment for participating in educational activities from Boheringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis and Mundipharma. R.J. reports grants from the NIHR and participation in a Boehringer Ingelheim primary care advisory board during this project. J.K. reports grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim, grants and personal fees from Chiesi Pharmaceuticals, grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, grants from MundiPharma, grants from TEVA, outside the submitted work, all paid to his institution; and J.K. holds 72.5% of shares in the General Practitioners Research Institute. K.L. has received personal fees for lectures and educational activities from AstraZeneca, Novartis, Boehringer Ingelheim and Chiesi and served on advisory boards arranged by AstraZeneca, GlaxoSmithKline, Novartis and Boehringer Ingelheim. L.M. has received payment for participating in educational activities, consultancy, or support to attend clinical meetings from Hero Espa{\~n}a, Merck-Allergopharma, ALK-Abell{\'o}, Laboratorios Jofre-Roig, Laboratorios Leti, Faes Farma, Novartis, Inmunotek, GSK, and Alter. D.P. has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundi-pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. H.P. in the last 3 years was paid by Teva to write a piece on supported self-management for their website. Organisations with which she is involved, or conferences/meetings at which she has spoken receive multi-company sponsorship. D.R. has in the last 3 years received payment for participating in educational activities, consultancy or support to attend clinical meetings from: AZ,BI, GSK, Chiesi, Novartis, Trudell, Meda, Regeneron and Medscape. He is a board member of the Primary care and allied health section of the European Academy of Allergy and clinical Immunology and vice president of the Respiratory Effectiveness Group. B.S. has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, MEDA and TEVA and has served on advisory boards arranged by AstraZeneca, Novartis, GlaxoSmithKline, Boehringer Ingelheim and MEDA. S.S. has served as a consultant for Boehringer Ingelheim, Genentech, GlaxoSmithKline, AstraZeneca, Propeller Health, Sanofi, and Regeneron; and received a grant from Propeller Health. All payments were made to his university. A.T. has grants for respiratory research from AstraZeneca, Chiesi and CSL Behring, and has additional consultancy or honoraria for educational work for GSK and Boehringer Ingelheim. S.T. holds grants related to COPD and asthma from the NIHR. I.T. has in the last 3 years received payment for participating in educational activities, consultancy or received grants from: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and ELPEN. She is the Editor in Chief of the npjPCRM. O.Y. holds a grant related to respiratory health from the NIHR. A.B., R.A., A.A.A., D.A., I.B., N.C., A.D., M.E., Fv.G., S.H., A.K., B.K., D.K., E.M., C.Mc., C.N., S.P., S.J.S., D.W., S.W. and A.K.T. declare no competing interests. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41533-021-00266-4",

language = "English",

volume = "32",

journal = "NPJ Primary Care Respiratory Medicine",

issn = "2055-1010",

publisher = "Nature Publishing Group",

number = "1",

}

Abdel-Aal, A, Lisspers, K, Williams, S, Adab, P , Adams, R, Agarwal, D, Barnard, A, Bouloukak, I, van Boven, JFM, Chavannes, N, Dickens, A, van Gemert, F, Escarrer, M, Haroon, S, Kayongo, A, Kirenga, B, Kocks, JWH, Kotz, D, Newby, C, McNulty, CAM, Metting, E, Moral, L, Papadakis, S, Pinnock, H, Price, D, Ryan, D, Singh, SJ, Correia-de-Sousa, J, Ställberg, B, Szefler, SJ, Taylor, SJC, Tsiligianni, I, Turner, A, Weller, D, Yusuf, O, Tabyshova, AK & Jordan, R 2022, 'Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise', NPJ Primary Care Respiratory Medicine, vol. 32, no. 1, 6. https://doi.org/10.1038/s41533-021-00266-4

TY - JOUR

T1 - Prioritising primary care respiratory research needs

T2 - results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise

AU - Abdel-Aal, Arwa

AU - Lisspers, Karin

AU - Williams, Siân

AU - Adab, Peymane

AU - Adams, Rachel

AU - Agarwal, Dhiraj

AU - Barnard, Amanda

AU - Bouloukak, Izolde

AU - van Boven, Job FM

AU - Chavannes, Niels

AU - Dickens, Andy

AU - van Gemert, Frederik

AU - Escarrer, Mercedes

AU - Haroon, Shamil

AU - Kayongo, Alex

AU - Kirenga, Bruce

AU - Kocks, Janwillem W H

AU - Kotz, Daniel

AU - Newby, Chris

AU - McNulty, Cliodna a M

AU - Metting, Esther

AU - Moral, Luis

AU - Papadakis, Sophia

AU - Pinnock, Hilary

AU - Price, David

AU - Ryan, Dermot

AU - Singh, Sally J

AU - Correia-de-Sousa, Jaime

AU - Ställberg, Björn

AU - Szefler, Stanley J

AU - Taylor, Steph J.C.

AU - Tsiligianni, Ioanna

AU - Turner, Alice

AU - Weller, David

AU - Yusuf, Osman

AU - Tabyshova, Aizhamal K

AU - Jordan, Rachel

N1 - Funding Information: P.A. holds grants related to respiratory epidemiology from the NIHR. She chairs the NIHR Public Health Research Funding Committee. Jv.B. has received consultancy fees, honorarium and research funding from AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini, Novartis, Nutricia, Pill Connect, Teva and Trudell Medical to consult, give lectures, provide advice and conduct independent research, all paid to his institution. J.C.S. has in the last 3 years received payment for participating in educational activities from Boheringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis and Mundipharma. R.J. reports grants from the NIHR and participation in a Boehringer Ingelheim primary care advisory board during this project. J.K. reports grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim, grants and personal fees from Chiesi Pharmaceuticals, grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, grants from MundiPharma, grants from TEVA, outside the submitted work, all paid to his institution; and J.K. holds 72.5% of shares in the General Practitioners Research Institute. K.L. has received personal fees for lectures and educational activities from AstraZeneca, Novartis, Boehringer Ingelheim and Chiesi and served on advisory boards arranged by AstraZeneca, GlaxoSmithKline, Novartis and Boehringer Ingelheim. L.M. has received payment for participating in educational activities, consultancy, or support to attend clinical meetings from Hero España, Merck-Allergopharma, ALK-Abelló, Laboratorios Jofre-Roig, Laboratorios Leti, Faes Farma, Novartis, Inmunotek, GSK, and Alter. D.P. has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundi-pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. H.P. in the last 3 years was paid by Teva to write a piece on supported self-management for their website. Organisations with which she is involved, or conferences/meetings at which she has spoken receive multi-company sponsorship. D.R. has in the last 3 years received payment for participating in educational activities, consultancy or support to attend clinical meetings from: AZ,BI, GSK, Chiesi, Novartis, Trudell, Meda, Regeneron and Medscape. He is a board member of the Primary care and allied health section of the European Academy of Allergy and clinical Immunology and vice president of the Respiratory Effectiveness Group. B.S. has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, MEDA and TEVA and has served on advisory boards arranged by AstraZeneca, Novartis, GlaxoSmithKline, Boehringer Ingelheim and MEDA. S.S. has served as a consultant for Boehringer Ingelheim, Genentech, GlaxoSmithKline, AstraZeneca, Propeller Health, Sanofi, and Regeneron; and received a grant from Propeller Health. All payments were made to his university. A.T. has grants for respiratory research from AstraZeneca, Chiesi and CSL Behring, and has additional consultancy or honoraria for educational work for GSK and Boehringer Ingelheim. S.T. holds grants related to COPD and asthma from the NIHR. I.T. has in the last 3 years received payment for participating in educational activities, consultancy or received grants from: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and ELPEN. She is the Editor in Chief of the npjPCRM. O.Y. holds a grant related to respiratory health from the NIHR. A.B., R.A., A.A.A., D.A., I.B., N.C., A.D., M.E., Fv.G., S.H., A.K., B.K., D.K., E.M., C.Mc., C.N., S.P., S.J.S., D.W., S.W. and A.K.T. declare no competing interests. Publisher Copyright: © 2022, The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - Respiratory diseases remain a significant cause of global morbidity and mortality and primary care plays a central role in their prevention, diagnosis and management. An e-Delphi process was employed to identify and prioritise the current respiratory research needs of primary care health professionals worldwide. One hundred and twelve community-based physicians, nurses and other healthcare professionals from 27 high-, middle- and low-income countries suggested 608 initial research questions, reduced after evidence review by 27 academic experts to 176 questions covering diagnosis, management, monitoring, self-management and prognosis of asthma, COPD and other respiratory conditions (including infections, lung cancer, tobacco control, sleep apnoea). Forty-nine questions reached 80% consensus for importance. Cross-cutting themes identified were: a need for more effective training of primary care clinicians; evidence and guidelines specifically relevant to primary care, adaption for local and low-resource settings; empowerment of patients to improve self-management; and the role of the multidisciplinary healthcare team.

AB - Respiratory diseases remain a significant cause of global morbidity and mortality and primary care plays a central role in their prevention, diagnosis and management. An e-Delphi process was employed to identify and prioritise the current respiratory research needs of primary care health professionals worldwide. One hundred and twelve community-based physicians, nurses and other healthcare professionals from 27 high-, middle- and low-income countries suggested 608 initial research questions, reduced after evidence review by 27 academic experts to 176 questions covering diagnosis, management, monitoring, self-management and prognosis of asthma, COPD and other respiratory conditions (including infections, lung cancer, tobacco control, sleep apnoea). Forty-nine questions reached 80% consensus for importance. Cross-cutting themes identified were: a need for more effective training of primary care clinicians; evidence and guidelines specifically relevant to primary care, adaption for local and low-resource settings; empowerment of patients to improve self-management; and the role of the multidisciplinary healthcare team.

KW - e-Delphi

KW - primary care

KW - research priorities

KW - respiratory disease

KW - asthma

KW - COPD

KW - tobacco

UR - http://ipcrg.org/resources/search-resources/prioritising-primary-care-respiratory-research-needs-results-from-the

UR - http://www.scopus.com/inward/record.url?scp=85123876694&partnerID=8YFLogxK

U2 - 10.1038/s41533-021-00266-4

DO - 10.1038/s41533-021-00266-4

M3 - Article

C2 - 35091570

SN - 2055-1010

VL - 32

JO - NPJ Primary Care Respiratory Medicine

JF - NPJ Primary Care Respiratory Medicine

IS - 1

M1 - 6

ER -

Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this